The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).
about
Supramaximal dose of candesartan in proteinuric renal diseaseHow Biomaterials Can Influence Various Cell Types in the Repair and Regeneration of the Heart after Myocardial InfarctionNon-invasive assessment of vascular alteration using ultrasoundVasculopathy of Aging and the Revised Cardiovascular ContinuumGenetic Research and Women's Heart Disease: a PrimerMedical Yoga Therapy.Cardiovascular disease risk, vascular health and erectile dysfunction among middle-aged, clinically depressed menIncreased prevalence of metabolic syndrome in individuals with osteoarthritis: an analysis of NHANES III data.Regulation of oxidative stress and cardioprotection in diabetes mellitus.The Salutary Influence of Forest Bathing on Elderly Patients with Chronic Heart Failure.Evaluation of the systemic micro- and macrovasculature in stable angina: A case-control study.Should we screen for masked hypertension in patient with vascular disease?The relationship between retinal microvascular abnormalities and coronary heart disease: a review.Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care.Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment.Aliskiren and valsartan combination therapy for the management of hypertension.Stopping the cardiovascular disease continuum: Focus on prevention.Cardio classics revisited--focus on the role of candesartan.Usefulness of the Doppler flow of the ophthalmic artery in the evaluation of carotid and coronary atherosclerosisNox2-dependent glutathionylation of endothelial NOS leads to uncoupled superoxide production and endothelial barrier dysfunction in acute lung injury.Nitric oxide synthetic pathway in red blood cells is impaired in coronary artery disease.A new paradigm in the treatment of the cardiovascular disease continuum: focus on prevention.Evaluation of the cardiovascular effects of methylmercury exposures: current evidence supports development of a dose-response function for regulatory benefits analysisOxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention?Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes.Clinical utility of fixed-combination telmisartan-amlodipine in the treatment of hypertension.Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular riskGenetic view on the phenomenon of combined diseases in man.Interferon-γ-mediated allograft rejection exacerbates cardiovascular disease of hyperlipidemic murine transplant recipients.Mechanisms of greater cardiomyocyte functions on conductive nanoengineered composites for cardiovascular applicationFunctionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction.Echocardiographic indices of left ventricular hypertrophy and diastolic function in hypertensive patients with preserved LVEF classified as dippers and non-dippers.Cholesterol and cardiovascular disease in the elderly. Facts and gaps.Arterial aging: pathophysiological principles.Risk-based classification of hypertension and the role of combination therapy.The Prevalence of the Risk Factors for Atherosclerosis among Type 2 Diabetic Patients Is Greater in the Progressive Stages of Chronic Kidney DiseaseMitochondrial targeted antioxidant Peptide ameliorates hypertensive cardiomyopathyIdentifying early cardiovascular disease to target candidates for treatment.Lactobacillus fermentum ME-3 - an antimicrobial and antioxidative probioticAntioxidant plasma concentration and supplementation in carotid intima media thickness.
P2860
Q24649685-E362D185-E019-4457-BC1C-710BC43C52CAQ26739723-5B5484D3-FE36-4064-BC5F-435CB3FBC4BCQ26764782-9901B9E5-3F86-4972-8398-D70E747A1AFAQ26851569-C9A48DF3-A51F-40CC-820B-2C58E576F46BQ28069638-41D065AD-07D6-44AF-BFB2-A7CE3E99048FQ30274750-7D4A9EFE-DB6D-4294-8B8E-96A925A25EF1Q33506250-09AF7C2B-DD38-44B2-A496-0E172E6E5F04Q33516685-991AA770-A6F9-4AD8-BDA4-DB5915E50F85Q33572259-FBD368D9-4FED-4C9D-B884-4666BA1A5168Q33616022-9B63C37C-A545-4F87-9898-669D1E5834D3Q33728667-41D36960-D123-4201-A8F1-B9D4B4D89CD3Q33888311-E8470A12-6610-49CB-B767-3AA883947CE5Q34070762-CEB58B70-714B-4FDB-B59A-9D3B702216EAQ34095380-44262D58-78E9-4D14-9052-86635521C602Q34128192-3C9B016E-F505-46EB-AC67-919DDD803058Q34139070-4BA19DC3-2AE2-45C6-AB05-17EBD5CF66A4Q34390558-2665F9EA-2FA0-40A2-93AF-5626C26061F0Q34417462-52AB5A19-DFAA-4E0F-994F-B91A8F3414A5Q34592129-A378335B-48A2-42FA-AA66-5954FA3951D4Q34726830-F1A4DB96-7B3F-4706-AD23-DD0DD1130FFEQ34934327-53689B07-2760-41B9-A1E7-6B8DDE8382CAQ34976766-501D2ABA-3819-4B25-A99A-FBEE73B570B1Q34980939-FD6AB10C-A07F-4A67-B38F-8CA01BBC86E2Q35167634-12672AA9-63E4-4486-898D-9139515C9D96Q35210513-4FD3B81B-7D2E-4170-AB83-D0EE77786189Q35210553-C4668FEB-E043-47D7-A64E-F8A2C5CB0BEDQ35539305-41863D07-CFFF-45ED-823E-3DD5A9C3B1AFQ35944277-16BAADF9-F941-40DA-BF66-F93AE70B0868Q36259538-836D4839-6D19-4D1E-B37D-16217635DE48Q36409175-559B0BD1-97D4-41D9-8A53-943A8622BBA4Q36675350-805874B9-6079-4654-B7FC-9724D112CAFFQ36829043-C541DBF2-9FDE-418D-B229-87B25C3186B3Q36863052-F1122234-793F-4CF4-823D-6E8AC8841A22Q37019596-52BF223A-0B49-4EE0-943F-036BF0B1B271Q37050143-470956DA-6A5B-40BF-9869-2581DBB676B6Q37057943-88F1D44F-9F7D-4752-8B14-B32B5A78C0CFQ37091220-AFC7D244-470A-44F3-B24E-EA3E6EE64836Q37104528-F3E47D66-1299-405B-B004-47925CABE66CQ37161945-6370E207-C5BC-452C-AAEC-871E1D2BC98AQ37176458-F897C17D-4D07-4C1E-B43E-307A55A144BD
P2860
The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease).
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The cardiovascular disease con ...... able coronary artery disease).
@ast
The cardiovascular disease con ...... able coronary artery disease).
@en
type
label
The cardiovascular disease con ...... able coronary artery disease).
@ast
The cardiovascular disease con ...... able coronary artery disease).
@en
prefLabel
The cardiovascular disease con ...... able coronary artery disease).
@ast
The cardiovascular disease con ...... able coronary artery disease).
@en
P2093
P1433
P1476
The cardiovascular disease con ...... able coronary artery disease).
@en
P2093
David L Hayes
Henry R Black
JoAnn E Manson
Jorge Plutzky
Victor J Dzau
William Stevenson
P304
P356
10.1161/CIRCULATIONAHA.106.655688
P407
P577
2006-12-01T00:00:00Z